Immucell (ICCC) Non-Current Debt (2010 - 2026)
Immucell's (ICCC) quarterly Non-Current Debt came in at $7.5 million in Q4 2025, down 17.17% YoY from $9.0 million in Q4 2024, and down 5.19% on a QoQ basis from $7.9 million in Q3 2025.
Immucell (ICCC) Non-Current Debt (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Non-Current Debt data on file, last reported at $7.5 million in Q4 2025.
- Quarterly Non-Current Debt fell 17.17% year-over-year to $7.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.5 million (down 17.17% YoY) and the FY2025 annual result came in at $7.5 million, down 17.17% from the prior year.
- Non-Current Debt eased to $7.5 million in Q4 2025, from $7.9 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $10.9 million in Q3 2023 to a low of $7.5 million in Q4 2025.
- A 5-year average of $9.2 million and a median of $9.1 million in 2022 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt rose 16.78% — and 2025, when it fell 17.17%.
- Tracing ICCC's Non-Current Debt over 5 years: stood at $8.3 million in 2021, then advanced by 10.38% to $9.2 million in 2022, then increased by 14.68% to $10.5 million in 2023, then fell by 14.23% to $9.0 million in 2024, then declined by 17.17% to $7.5 million in 2025.
- The last three Non-Current Debt figures came in at $7.5 million (Q4 2025), $7.9 million (Q3 2025), and $8.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 8.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.30 Mn |
| Dec 31, 2025 | 7.49 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Jun 30, 2025 | 8.26 Mn |
| Mar 31, 2025 | 10.25 Mn |
| Dec 31, 2024 | 9.04 Mn |
| Sep 30, 2024 | 9.42 Mn |
| Jun 30, 2024 | 9.80 Mn |
| Mar 31, 2024 | 10.17 Mn |
| Dec 31, 2023 | 10.54 Mn |
| Sep 30, 2023 | 10.90 Mn |
| Jun 30, 2023 | 8.64 Mn |
| Mar 31, 2023 | 8.92 Mn |
| Dec 31, 2022 | 9.19 Mn |
| Sep 30, 2022 | 9.48 Mn |
| Jun 30, 2022 | 9.73 Mn |
| Mar 31, 2022 | 9.98 Mn |
| Dec 31, 2021 | 8.33 Mn |
| Sep 30, 2021 | 8.55 Mn |
| Jun 30, 2021 | 8.35 Mn |